Sandoz Inc. is once again temporarily delaying the launch of Zarxio (filgrastim-sndz), its biosimilar to Neupogen (filgrastim), while a dispute with Amgen Inc. over the Biologics Price Competition and Innovation Act’s patent information exchange provisions makes its way through the court system.
The Novartis AG subsidiary will not launch Zarxio in the U.S. until the earlier of May 11 or a ruling by the U.S. Court of Appeals for the Federal...